CytomX Therapeutics (CTMX) PT Lowered to $8 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Price: $2.29 +5.05%
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
BTIG analyst Kaveri Pohlman lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $8.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- CytomX Therapeutics to Present at Upcoming November Investor Conferences
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
